Application of chidamide combined PD-1 / PD-L1 antibody medicine and combined medicine
Through the combined use of cidabenamine and PD-1/PD-L1 antibody drugs, the problem of poor efficacy of advanced urothelial cancer on the existing PD-1/PD-L1 monotherapy was solved, and the treatment effect was significantly improved , provides a new treatment plan for advanced urothelial carcinoma.
Patent Information
- Application Number
- CN202410710784.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-03
- Filing Date
- 2024-06-03
- Publication Date
- 2024-12-03
AI Technical Summary
The existing PD-1/PD-L1 monotherapy has poor efficacy in advanced bladder cancer, especially in patients with primary and secondary resistance, where effective treatment options are lacking, and cedabenamine combined with There are no research reports on the application of PD-1/PD-L1 antibody drugs in the treatment of urothelial carcinoma.
Using Cedarbenamine as a histone deacetylase inhibitor combined with PD-1/PD-L1 antibody drugs, such as tirelizumab, is used to treat advanced urothelial carcinoma, by adjusting the immune microenvironment to enhance Anti-tumor immune response.
It significantly improved the objective response rate and progression-free survival time of urothelial cancer, which was nearly twice as high as monotherapy treatment, demonstrated the synergistic effect of sidaponamine and PD-1/PD-L1 inhibitors, providing A new effective method for treating advanced urothelial carcinoma.
Smart Images

Figure CN119055778A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of chemical pharmacy, and specifically relates to the use of chidamide combined with PD-1 / PD-L1 antibody drugs in the treatment of urothelial carcinoma and a combined drug. Background Art
[0002] Urothelial carcinoma is a malignant tumor that occurs in the urothelium. Urothelial carcinoma includes bladder cancer, renal pelvis cancer, and urethral cancer. 90% of urothelial tumors originate from the bladder, 8% from the renal pelvis, and 2% from the ureter and urethra. Urothelial carcinoma is classified based on pathological results, while bladder cancer is classified based on the site of onset. The vast majority of bladder cancers are urothelial carcinomas, accounting for more than 90%. Bladder cancer is generally considered to be bladder urothelial carcinoma. Epidemiological data on bladder cancer show that the incidence and mortality of urothelial carcinoma rank first among male genitourinary system tumors; data from the China National Cancer Registry show that bladder cancer ranks seventh among male tumors in China; in 2022, 81,000 new cases of bladder cancer were diagnosed in the United States and 17,000 patients died from bladder cancer; in 2016, 80,500 cases of bladder cancer were diagnosed in my country, and 32,900 patients died from bladder cancer, including 25,100 male patients and 7,800 female patients; about 75% of patients with bladder urothelial carcinoma initially developed non-muscle invasive type, about 5% of bladder cancer patients were found to have metastatic lesions at the time of diagnosis, and of the 20% of patients with muscle-invasive bladder cancer, about 30% will progress to metastatic urothelial carcinoma; metastatic urothelial carcinoma cannot be cured and has a poor prognosis, with a 5-year overall survival rate of about 5.4%.
[0003] Histone deacetylases (HDACs) are involved in chromatin remodeling and play a key role in epigenetic regulation of genes. Epigenetic factors play a role in multiple aspects of the immune cycle. Histone deacetylase inhibitors (HDAC inhibitor, HDACi) can improve immune recognition by restoring the expression of various tumor-associated antigens (TAAs), major histocompatibility complex (MHC) molecules, and the generation of antigen-presenting cells (APCs). Epigenetic agents may also enhance the migration of T cells into the tumor microenvironment by targeting the production of TH1 chemokines and the generation of immunosuppressive cells.
[0004] Chidamide is the first subtype-selective HDACi independently developed and synthesized by Shenzhen Chipscreen Biotech Co., Ltd. It is the only HDACi drug approved by the National Medical Products Administration for clinical trials. Studies have shown that Chidamide has regulatory activity on tumor cells, tumor microenvironment, and immune system function.
[0005] PD-1 (programmed death receptor 1) is an important immunosuppressive molecule and belongs to the immunoglobulin superfamily. It has at least two ligands, one is PD-L1 and the other is PD-L2. Immune regulation targeting PD-1 is of great significance for fighting tumors, infections, and autoimmune diseases. PD-1's ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. The combination of PD-1 and PD-L1 initiates the programmed death of T cells, allowing tumor cells to escape immune system. PD-1 is an immune checkpoint that prevents autoimmunity.
[0006] The first-line treatment of choice for bladder cancer includes cisplatin-based chemotherapy, and PD-1 / PD-L1 antibody drugs are the preferred second-line treatment for advanced bladder cancer. Currently, seven blocking antibodies targeting the PD-1 pathway have been approved by the National Medical Products Administration (NMPA) or the U.S. Food and Drug Administration (FDA) for patients with metastatic urothelial carcinoma. These drugs are currently approved for second-line treatment after failure of platinum chemotherapy. Among them, they include Tislelizumab, Toripalimab, Nivolumab, Pembrolizumab targeting the PD-1 receptor, and Atezolizumab, Durvalumab, and Avelumab targeting the PD-L1 receptor. However, the efficacy of immune PD-1 / PD-L1 monotherapy in advanced bladder cancer is poor, and more treatment modes are urgently needed to improve the objective response rate and prolong survival. The clinical manifestations of failure of immune checkpoint inhibitor (ICI) treatment can be divided into two categories: one is primary resistance, that is, most patients who have not been screened for markers do not benefit from ICI monotherapy (ICI-refractory, ICI-refractory); the other is secondary resistance, that is, some responders develop treatment resistance after a period of response (ICT-relapse, ICI-relapse). Therefore, more effective and safe treatment options are needed for patients with solid tumors who progress or relapse after ICI treatment.
[0007] Although scientists have studied and explored the combined use of HDACi (such as belinostat and vorinostat) and PD-1 / PD-L1 antibody drugs to treat locally recurrent or advanced urothelial carcinoma, there are no existing technical studies and reports on the combined use of cedabenbine and PD-1 / PD-L1 antibody drugs (such as tislelizumab) to treat locally recurrent or advanced urothelial carcinoma. Summary of the invention
[0008] The present invention provides the use of a HADC inhibitor combined with a PD-1 / PD-L1 antibody drug in the preparation of a drug for preventing and / or treating urothelial carcinoma; wherein the HADC inhibitor is chidamide and its derivatives.
[0009] In some embodiments, in the above-mentioned use, the derivative of chidamide is selected from pharmaceutically acceptable salts, enantiomers, crystalline form A and crystalline form B thereof.
[0010] The structure of Chidamide is disclosed in CN101906076A, CN103833626A discloses the crystalline form A and the crystalline form B of Chidamide, and CN103880736A discloses the enantiomers of Chidamide.
[0011] In some embodiments, in the above-mentioned use, the PD-1 / PD-L1 antibody drug is selected from Tislelizumab, Toripalimab, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, and Avelumab.
[0012] In some preferred embodiments, the PD-1 / PD-L1 antibody drug is Tislelizumab.
[0013] In some embodiments, in the above use, the urothelial carcinoma is advanced urothelial carcinoma.
[0014] In some preferred embodiments, the urothelial carcinoma is locally advanced or metastatic urothelial carcinoma.
[0015] In some preferred embodiments, the urothelial carcinoma is a urothelial carcinoma whose primary site is the bladder, ureter or renal pelvis.
[0016] In some preferred embodiments, the urothelial carcinoma is urothelial carcinoma that has metastasized to the lung, bone, liver, distant lymph nodes or elsewhere.
[0017] In some more preferred embodiments, the urothelial carcinoma is locally advanced or metastatic urothelial carcinoma that has previously received platinum-based chemotherapy.
[0018] In some even more preferred embodiments, the urothelial carcinoma may be urothelial carcinoma that has progressed after receiving second-line immunotherapy alone and has not yet been replaced by other treatment options.
[0019] In some embodiments, in the above-mentioned use, the unit dose of the chidamide and its derivatives is 5-60 mg, preferably 20-40 mg, and most preferably 30 mg.
[0020] Different PD-1 / PD-L1 antibody drugs use different dosages and dosing intervals. The recommended dose of tislelizumab is 200 mg, administered once every 3 weeks; the recommended dose of atezolizumab is 1200 mg, administered once every 3 weeks. The recommended doses of toripalimab, nivolumab, pembrolizumab, durvalumab, and avelumab are calculated based on body weight, for example, the recommended dose of toripalimab or nivolumab is 3 mg / kg, administered once every 2 weeks; the recommended dose of pembrolizumab is 2 mg / kg, administered once every 3 weeks; the recommended dose of durvalumab and avelumab is 10 mg / kg, administered once every 2 weeks.
[0021] In some embodiments, in the above-mentioned uses, the unit dose of the PD-1 / PD-L1 antibody drug is 80-1500 mg, preferably 100-1200 mg; wherein, the unit dose of tilelizumab is 100-200 mg, preferably 200 mg; the unit dose of toripalimab or nivolumab is 120-300 mg, preferably 150-240 mg; the unit dose of pembrolizumab is 80-200 mg, preferably 100-160 mg; the unit dose of atezolizumab is 600-1200 mg, preferably 1200 mg; the unit dose of durvalumab and avelumab is 400-1000 mg, preferably 500-800 mg.
[0022] In some embodiments, in the above-mentioned uses, the chidamide and its derivatives need to be administered twice a week. The PD-1 / PD-L1 antibody drugs need to be administered once every 2-3 weeks; among them, tislelizumab, pembrolizumab, and atezolizumab are administered once every 3 weeks; toripalimab, nivolumab, durvalumab, and avelumab are administered once every 2 weeks.
[0023] In a second aspect, the present invention provides the use of a HADC inhibitor for preparing a drug for preventing and / or treating urothelial carcinoma in combination with a PD-1 / PD-L1 antibody drug; the HADC inhibitor is chidamide and its derivatives.
[0024] In some embodiments, in the above-mentioned use, the derivative of chidamide is selected from pharmaceutically acceptable salts, enantiomers, crystalline form A and crystalline form B thereof.
[0025] The structure of Chidamide is disclosed in CN101906076A, CN103833626A discloses the crystalline form A and the crystalline form B of Chidamide, and CN103880736A discloses the enantiomers of Chidamide.
[0026] In some embodiments, in the above-mentioned use, the PD-1 / PD-L1 antibody drug is selected from Tislelizumab, Toripalimab, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, and Avelumab.
[0027] In some preferred embodiments, the PD-1 / PD-L1 antibody drug is Tislelizumab.
[0028] In some embodiments, in the above use, the urothelial carcinoma is advanced urothelial carcinoma.
[0029] In some preferred embodiments, the urothelial carcinoma is locally advanced or metastatic urothelial carcinoma.
[0030] In some preferred embodiments, the urothelial carcinoma is a urothelial carcinoma whose primary site is the bladder, ureter or renal pelvis.
[0031] In some preferred embodiments, the urothelial carcinoma is urothelial carcinoma that has metastasized to the lung, bone, liver, distant lymph nodes or elsewhere.
[0032] In some more preferred embodiments, the urothelial carcinoma is locally advanced or metastatic urothelial carcinoma that has previously received platinum-based chemotherapy.
[0033] In some even more preferred embodiments, the urothelial carcinoma may be urothelial carcinoma that has progressed after receiving second-line immunotherapy alone and has not yet been replaced by other treatment options.
[0034] In some embodiments, in the above-mentioned use, the unit dose of the chidamide and its derivatives is 5-60 mg, preferably 20-40 mg, and most preferably 30 mg.
[0035] Different PD-1 / PD-L1 antibody drugs use different dosages and dosing intervals. The recommended dose of tislelizumab is 200 mg, administered once every 3 weeks; the recommended dose of atezolizumab is 1200 mg, administered once every 3 weeks. The recommended doses of toripalimab, nivolumab, pembrolizumab, durvalumab, and avelumab are calculated based on body weight, for example, the recommended dose of toripalimab or nivolumab is 3 mg / kg, administered once every 2 weeks; the recommended dose of pembrolizumab is 2 mg / kg, administered once every 3 weeks; the recommended dose of durvalumab and avelumab is 10 mg / kg, administered once every 2 weeks.
[0036] In some embodiments, in the above-mentioned uses, the unit dose of the PD-1 / PD-L1 antibody drug is 80-1500 mg, preferably 100-1200 mg; wherein, the unit dose of tilelizumab is 100-200 mg, preferably 200 mg; the unit dose of toripalimab or nivolumab is 120-300 mg, preferably 150-240 mg; the unit dose of pembrolizumab is 80-200 mg, preferably 100-160 mg; the unit dose of atezolizumab is 600-1200 mg, preferably 1200 mg; the unit dose of durvalumab and avelumab is 400-1000 mg, preferably 500-800 mg.
[0037] In some embodiments, in the above-mentioned uses, the chidamide and its derivatives need to be administered twice a week. The PD-1 / PD-L1 antibody drugs need to be administered once every 2-3 weeks; among them, tislelizumab, pembrolizumab, and atezolizumab are administered once every 3 weeks; toripalimab, nivolumab, durvalumab, and avelumab are administered once every 2 weeks.
[0038] In a third aspect, the present invention also provides a combination drug for preventing and / or treating urothelial carcinoma, comprising a HDAC inhibitor and a PD-1 / PD-L1 antibody drug; the HDAC inhibitor is chidamide and its derivatives.
[0039] In some embodiments, in the above combination drug, the derivative of chidamide is selected from its pharmaceutically acceptable salts, enantiomers, crystalline form A and crystalline form B.
[0040] In some embodiments, in the above-mentioned combination drugs, the PD-1 / PD-L1 antibody drug is selected from Tislelizumab, Toripalimab, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, and Avelumab; preferably, Tislelizumab.
[0041] In some embodiments, in the above-mentioned combination drugs, the chidamide and PD-1 / PD-L1 antibody drugs are both in the form of preparations; the chidamide is in the form of oral preparations, preferably oral tablets; the PD-1 / PD-L1 antibody drug is in the form of injection preparations. Among them, injection preparations refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, as well as sterile powders or concentrated solutions for preparation into solutions or suspensions before clinical use; according to the site of administration, they can be divided into intradermal injections, subcutaneous injections, intramuscular injections, intravenous injections, etc. In a preferred embodiment, the PD-1 / PD-L1 antibody drug is in the form of intravenous injections for intravenous infusion.
[0042] In some embodiments, in the above-mentioned combination drug, the unit dose of the chidamide and its derivatives is 5-60 mg, preferably 20-40 mg, and most preferably 30 mg.
[0043] In some embodiments, in the above-mentioned combination drugs, the unit dose of the PD-1 / PD-L1 antibody drug is 80-1500 mg, preferably 100-1200 mg; among them, the unit dose of tilelizumab is 100-200 mg, preferably 200 mg; the unit dose of toripalimab or nivolumab is 120-300 mg, preferably 150-240 mg; the unit dose of pembrolizumab is 80-200 mg, preferably 100-160 mg; the unit dose of atezolizumab is 600-1200 mg, preferably 1200 mg; the unit dose of durvalumab and avelumab is 400-1000 mg, preferably 500-800 mg.
[0044] In some embodiments, in the above method, the urothelial carcinoma is advanced urothelial carcinoma.
[0045] In some preferred embodiments, the urothelial carcinoma is locally advanced or metastatic urothelial carcinoma.
[0046] In some preferred embodiments, the urothelial carcinoma is a urothelial carcinoma whose primary site is the bladder, ureter or renal pelvis.
[0047] In some preferred embodiments, the urothelial carcinoma is urothelial carcinoma that has metastasized to the lung, bone, liver, distant lymph nodes or elsewhere.
[0048] In some more preferred embodiments, the urothelial carcinoma is locally advanced or metastatic urothelial carcinoma that has previously received platinum-based chemotherapy.
[0049] In some even more preferred embodiments, the urothelial carcinoma may be urothelial carcinoma that has progressed after receiving second-line immunotherapy alone and has not yet been replaced by other treatment options.
[0050] In a fourth aspect, the present invention further provides a method for preventing and / or treating urothelial carcinoma, comprising administering a therapeutically effective amount of the combination drug described in the third aspect to a patient in need thereof.
[0051] In some embodiments, in the above method, the urothelial carcinoma is advanced urothelial carcinoma.
[0052] In some preferred embodiments, the urothelial carcinoma is locally advanced or metastatic urothelial carcinoma.
[0053] In some preferred embodiments, the urothelial carcinoma is a urothelial carcinoma whose primary site is the bladder, ureter or renal pelvis.
[0054] In some preferred embodiments, the urothelial carcinoma is urothelial carcinoma that has metastasized to the lung, bone, liver, distant lymph nodes or elsewhere.
[0055] In some more preferred embodiments, the urothelial carcinoma is locally advanced or metastatic urothelial carcinoma that has previously received platinum-based chemotherapy.
[0056] In some even more preferred embodiments, the urothelial carcinoma may be urothelial carcinoma that has progressed after receiving second-line immunotherapy alone and has not yet been replaced by other treatment options.
[0057] Technical terms of the present invention:
[0058] In the following description, certain specific details are set forth in order to provide a thorough understanding of the various embodiments. However, it will be appreciated by those skilled in the art that the present invention may be implemented without these details. In other cases, well-known structures are not shown or described in detail to avoid unnecessarily obscuring the description of the embodiments. Unless the context otherwise requires, throughout the specification and claims, the words "comprise" and variations thereof, such as "comprises" and "comprising", should be interpreted as open-ended inclusive meanings, i.e., "including but not limited to". In addition, the titles provided herein are merely for convenience and are not intended to explain the scope or meaning of the claimed invention.
[0059] "Some embodiments" or "embodiments" mentioned throughout this specification means that the specific features, structures or characteristics described with respect to the embodiment are included in at least one embodiment. Therefore, the phrases "in some embodiments" or "in an embodiment" appearing in different places throughout this specification do not necessarily all refer to the same embodiment. In addition, the specific features, structures or characteristics can be combined in any suitable manner in one or more embodiments. Moreover, as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural indicators unless the context clearly dictates otherwise. It should also be noted that the term "or" is generally used in a sense that includes "and / or" unless the context clearly dictates otherwise.
[0060] In the present invention, the term "treatment" refers to administering or applying a therapeutic agent to a subject, or performing a step or pattern on a subject, the purpose of which is to obtain a therapeutic benefit for a disease or health-related condition, such as effectively improving the intrinsic pathological conditions and clinical manifestations of urothelial carcinoma in this article.
[0061] In the present invention, the term "prevent" means to reduce or completely inhibit to any extent to achieve the desired result. For example, compared to normal, the activity or symptom level can be reduced by 5%, 10%, 20%, 30%, 50%, 75%, 90%, 99% or more, or any range covered herein.
[0062] The term "therapeutically effective amount" means the amount of a compound that is effective to produce a desired therapeutic effect. Depending on the compound, the symptoms and their severity, and the age of the mammal being treated, the amount of the compound disclosed herein that is "therapeutically effective" will also vary, but can be routinely determined by a person of ordinary skill in the art based on his or her knowledge in combination with the disclosure of the present invention.
[0063] Beneficial effects of the present invention:
[0064] The overall objective response rate (ORR) of the combined treatment of urothelial carcinoma with chidamide and PD-1 / PD-L1 inhibitor tislelizumab claimed in the present invention is 41.7%, and the progression-free survival time (mPFS) achieved by 50% of the patients is 4.6 months; while the objective response rate (ORR) of tislelizumab monotherapy for urothelial carcinoma is 24.8%, and the progression-free survival (PFS) is 2.1 months. Chidamide has not been reported to be used clinically to treat urothelial carcinoma. It can be seen that the combination of chidamide and tislelizumab has a nearly 1-fold improvement in the objective response rate and more than 1-fold improvement in the progression-free survival time in the treatment of urothelial carcinoma compared to tislelizumab alone, indicating that the HDAC inhibitors (such as chidamide) and PD-1 / PD-L1 inhibitors (such as tislelizumab) claimed in the present invention can exert unexpected synergistic effects, and the combination therapy shows unexpected efficacy in the treatment of advanced urothelial carcinoma, providing a new treatment method for the treatment of advanced urothelial carcinoma. BRIEF DESCRIPTION OF THE DRAWINGS
[0065] Figure 1 Shows CT scans of the primary tumor in a patient with urothelial carcinoma before and after treatment with cedabenb plus tislelizumab.
[0066] Figure 2 This chart shows the progression-free survival statistics of patients with urothelial carcinoma after treatment with cedabenb combined with tislelizumab. Specific implementation plan
[0067] Unless otherwise defined, all technical and scientific terms in the present invention have the same meaning as those commonly understood by those skilled in the art. Other various forms of modification, substitution or change may be made according to common technical knowledge and customary means in the art without departing from the above basic technical concept of the present invention.
[0068] The present invention is described in detail below by examples, but it is not intended to limit the present invention in any adverse way. The compounds of the present invention can be prepared by a variety of synthesis methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by the combination thereof with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art, and preferred embodiments include but are not limited to the embodiments of the present invention. It will be apparent to those skilled in the art that various changes and improvements are made to the specific embodiments of the present invention without departing from the spirit and scope of the present invention, and they should also be regarded as the protection scope of the present invention.
[0069] Example 1 An open, single-arm, phase II clinical study on the efficacy and safety of chidamide combined with immunotherapy in patients with locally advanced or metastatic urothelial carcinoma who have previously received platinum-based chemotherapy
[0070] An open, single-arm, single-center phase II clinical study was conducted to evaluate the efficacy and safety of chidamide combined with tislelizumab in the treatment of patients with locally advanced or metastatic urothelial carcinoma who had failed first-line platinum treatment or were intolerant to platinum.
[0071] The inclusion criteria for patients in this study were as follows:
[0072] 1) Histological diagnosis of transitional cell carcinoma or urothelial carcinoma;
[0073] 2) Patients with inoperable disease or lymph node metastasis or distant metastasis who have relapsed or progressed during adjuvant first-line platinum-based chemotherapy;
[0074] 3) patients who received secondary chemotherapy could be included, but the period from the end of the first chemotherapy to the start of the second chemotherapy was more than 12 months;
[0075] 4) Subjects who received neoadjuvant or adjuvant chemotherapy and experienced disease progression within 12 months after the last dose will be considered to have received systemic chemotherapy in the setting of cancer metastasis;
[0076] 5) Patients who have progressed on second-line immunotherapy and have not switched to other treatment options can be included in the study;
[0077] 6) Having measurable target lesions (not treated with radiotherapy);
[0078] 7) ECOG score: 0-2 points;
[0079] 8) Patients with brain metastasis and previous treatment of urothelial transitional cell carcinoma with more than 2 lines of cytotoxic chemotherapy were excluded.
[0080] According to the above patient inclusion criteria, a total of 26 patients were enrolled from January 2021 to September 2022. Among the 26 patients, 20 were male, accounting for 76.9%, and 6 were female, accounting for 23.1%; the age range was 31 to 74 years old, with a median of 62 years old; 3 patients (11.5%) had an ECOG score of 0, 22 patients (84.6%) had an ECOG score of 1, and 1 patient (3.8%) had an ECOG score of 2; the primary site of the tumor in 17 patients (65.4%) was the bladder, 5 patients (19.2%) had the ureter, and 4 patients (15.4%) had the ureter. ) The primary site of the tumor was the renal pelvis; 8 patients (30.8%) had tumor metastasis to the lung, 8 patients (30.8%) had tumor metastasis to the bone, 5 patients (19.2%) had tumor metastasis to the liver, 12 patients (46.2%) had tumor metastasis to distant lymph nodes, and 4 patients (15.4%) had tumor metastasis to other parts; all 26 patients had received platinum-containing chemotherapy, of which 6 patients (23.1%) had received PD-1 / PD-L1 immunotherapy alone; 22 patients (84.6%) had received only first-line treatment, and 4 patients (15.4%) had received second-line treatment.
[0081] Before the start of treatment, CT scans were performed on the primary tumors of 26 patients and the records were kept. The treatment was started, with a 3-week treatment cycle. Tislelizumab 200 mg was intravenously infused in the first week, and cedabenb was administered twice a week for 3 weeks, 30 mg each time. Treatment continued until disease progression, intolerable toxicity, withdrawal of informed consent, or death, and the maximum treatment period was 2 years. After such a treatment cycle, the patient's tumor condition was observed regularly by CT scan. Examples of CT scans of primary tumors of some patients are shown in the attached Figure 1 The treatment status of the patients was evaluated according to the RECIST efficacy criteria for solid tumors.
[0082] As of September 30, 2022, among the 26 patients, 1 was lost to follow-up, 1 withdrew from the study early due to comorbidities as determined by the investigator, and the remaining 24 patients were eligible for clinical efficacy evaluation, of which 8 were still in the group. The current statistical results are shown in Table 1 and Appendix Figure 2 As shown:
[0083] Table 1: Clinical efficacy statistical results
[0084] Efficacy indicators Number of cases Proportion Objective response rate (ORR) 10 41.7% Complete remission (CR) 2 8.3% Partial response (PR) 8 33.3% Stable disease (SD) 5 20.8% Progressive disease (PD) 9 37.5% Disease control rate (DCR) 15 62.5%
[0085] Note: ORR=CR+PR; DCR=CR+PR+SD
[0086] According to Table 1 and Appendix Figure 2It can be seen that the overall objective response rate (ORR) is 41.7%, and the progression-free survival time (mPFS) achieved by 50% of patients is 4.6 months; while the objective response rate (ORR) of tislelizumab monotherapy for urothelial carcinoma is 24.8%, and the progression-free survival (PFS) is 2.1 months. Chidamide has not been reported to be used clinically to treat urothelial carcinoma. It can be seen that the combination of chidamide and tislelizumab has a nearly 1-fold improvement in the objective response rate and more than 1-fold improvement in the progression-free survival time compared to tislelizumab monotherapy for urothelial carcinoma, indicating that the HDAC inhibitors (such as chidamide) and PD-1 / PD-L1 inhibitors (such as tislelizumab) claimed in the present invention can play an unexpected synergistic role and be used in combination to treat urothelial carcinoma.
[0087] In addition, among the 26 patients, the vast majority of adverse reactions were grade 1 to 2, the overall safety was controllable, and the combination of the two drugs did not cause toxicity duplication or new adverse events.
[0088] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Use of a HADC inhibitor in combination with a PD-1 / PD-L1 antibody drug in the preparation of a drug for preventing and / or treating urothelial carcinoma; the HADC inhibitor is chidamide and its derivatives; Preferably, the derivative of chidamide is selected from pharmaceutically acceptable salts, enantiomers, crystalline form A and crystalline form B thereof; Preferably, the PD-1 / PD-L1 antibody drug is selected from Tislelizumab, Toripalimab, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, and Avelumab; more preferably Tislelizumab.
2. The use according to claim 1, characterized in that: The urothelial carcinoma is advanced urothelial carcinoma; Preferably, the urothelial carcinoma is locally advanced or metastatic urothelial carcinoma; Preferably, the urothelial carcinoma is a urothelial carcinoma whose primary site is the bladder, ureter or renal pelvis; Preferably, the urothelial carcinoma is urothelial carcinoma metastatic to the lung, bone, liver, distant lymph nodes or other places; More preferably, the urothelial carcinoma is locally advanced or metastatic urothelial carcinoma that has previously received platinum-based chemotherapy; Also preferably, the urothelial carcinoma may be a urothelial carcinoma that has progressed after receiving second-line immunotherapy alone and has not yet been replaced by other treatment options.
3. The use according to claim 1, characterized in that: The unit dose of the chidamide and its derivatives is 5-60 mg, preferably 20-40 mg, and most preferably 30 mg; The unit dose of the PD-1 / PD-L1 antibody drug is 80-1500 mg, preferably 100-1200 mg; among them, the unit dose of tislelizumab is 100-200 mg, preferably 200 mg; the unit dose of toripalimab or nivolumab is 120-300 mg, preferably 150-240 mg; the unit dose of pembrolizumab is 80-200 mg, preferably 100-160 mg; the unit dose of atezolizumab is 600-1200 mg, preferably 1200 mg; the unit dose of durvalumab and avelumab is 400-1000 mg, preferably 500-800 mg.
4. The use according to claim 1, characterized in that: The chidamide and its derivatives need to be administered twice a week; The PD-1 / PD-L1 antibody drugs need to be administered once every 2-3 weeks; among them, tislelizumab, pembrolizumab, and atezolizumab are administered once every 3 weeks; toripalimab, nivolumab, durvalumab, and avelumab are administered once every 2 weeks.
5. Use of a HADC inhibitor in the preparation of a drug for preventing and / or treating urothelial carcinoma in combination with a PD-1 / PD-L1 antibody drug; the HADC inhibitor is chidamide and its derivatives; Preferably, the derivative of chidamide is selected from pharmaceutically acceptable salts, enantiomers, crystalline form A and crystalline form B thereof; Preferably, the PD-1 / PD-L1 antibody drug is selected from Tislelizumab, Toripalimab, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, and Avelumab; more preferably Tislelizumab; Preferably, the urothelial carcinoma has the definition as claimed in claim 2; Preferably, the chidamide and its derivatives are as defined in claim 3 or 4; Preferably, the PD-1 / PD-L1 antibody drug has the definition as claimed in claim 3 or 4.
6. A combined drug for preventing and / or treating urothelial carcinoma, comprising a HADC inhibitor and a PD-1 / PD-L1 antibody drug; the HDAC inhibitor is chidamide and its derivatives; Preferably, the derivative of chidamide is selected from pharmaceutically acceptable salts, enantiomers, crystalline form A and crystalline form B thereof; Preferably, the PD-1 / PD-L1 antibody drug is selected from Tislelizumab, Toripalimab, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, and Avelumab; preferably Tislelizumab.
7. The combination drug according to claim 6, wherein both the chidamide and the PD-1 / PD-L1 antibody drug are in the form of preparations; the chidamide is in the form of an oral preparation, preferably an oral tablet; and the PD-1 / PD-L1 antibody drug is in the form of an injectable preparation.
8. The combined drug according to claim 6, characterized in that: The unit dose of the chidamide and its derivatives is 5-60 mg, preferably 20-40 mg, and most preferably 30 mg; The unit dose of the PD-1 / PD-L1 antibody drug is 80-1500 mg, preferably 100-1200 mg; among them, the unit dose of tislelizumab is 100-200 mg, preferably 200 mg; the unit dose of toripalimab or nivolumab is 120-300 mg, preferably 150-240 mg; the unit dose of pembrolizumab is 80-200 mg, preferably 100-160 mg; the unit dose of atezolizumab is 600-1200 mg, preferably 1200 mg; the unit dose of durvalumab and avelumab is 400-1000 mg, preferably 500-800 mg.
9. The combined drug according to claim 6, characterized in that: The urothelial carcinoma is advanced urothelial carcinoma; Preferably, the urothelial carcinoma is locally advanced or metastatic urothelial carcinoma; Preferably, the urothelial carcinoma is a urothelial carcinoma whose primary site is the bladder, ureter or renal pelvis; Preferably, the urothelial carcinoma is urothelial carcinoma metastatic to the lung, bone, liver, distant lymph nodes or other places; More preferably, the urothelial carcinoma is locally advanced or metastatic urothelial carcinoma that has previously received platinum-based chemotherapy; Also preferably, the urothelial carcinoma may be a urothelial carcinoma that has progressed after receiving second-line immunotherapy alone and has not yet been replaced by other treatment options.
10. A method for preventing and / or treating urothelial carcinoma, comprising administering a therapeutically effective amount of the combined drug according to any one of claims 6 to 9 to a patient in need thereof.
Citation Information
Patent Citations
Naphthaline amide derivative serving as protein kinase inhibitor and histone deacetylase inhibitor and preparation method and application thereof
CN101906076A
Crystal form of chidamide and preparation method and application thereof
CN103833626A
E-configuration benzamide compounds, and pharmaceutical preparation application thereof
CN103880736A
Cited By
Antibody-drug conjugate and use thereof
WO2026219284A1
